消息面上,兆科眼科此前公布,公司已与Interpharma Public Company Limited就于泰国商业化NVK002(一种控制近视加深的创新疗法);BRIMOCHOL™PF(一种治疗老花眼的创新药物);以及六款针对青光眼的仿制药(贝美前列素、贝美素噻吗洛尔、拉坦前列素、拉坦噻吗、曲伏前列素及曲伏噻吗)分别订立三份分销及供应协议。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.